Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 821 to 830 of 1090 total matches.
Aripiprazole (Abilify) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003 (Issue 1150)
; 3:479).
DRUG INTERACTIONS — When given with 2D6 inhibitors such as quinidine, fluoxetine
(Prozac ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • May 12, 2014 (Issue 1442)
with use of a PDE5 inhibitor.
DRUG INTERACTIONS — Like the other PDE5
inhibitors, avanafil is metabolized ...
The FDA has approved avanafil (Stendra – Vivus),
an oral phosphodiesterase type-5 (PDE5) inhibitor,
for treatment of erectile dysfunction. It is the fifth
PDE5 inhibitor to be approved for this indication.
Advertisements on Stendra’s website imply that
it has a faster onset of action than other PDE5
inhibitors.
ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
seizures, coma, cardiac
arrhythmias, and death.
DRUG INTERACTIONS — ZTlido may enhance the
toxicity ...
A lidocaine 1.8% patch (ZTlido – Scilex) has been
approved by the FDA for treatment of pain associated
with postherpetic neuralgia (PHN). A lidocaine 5%
patch (Lidoderm, and generics) was approved earlier
for the same indication and has been used off-label
for treatment of other types of localized pain. Both
of these patches are available only by prescription.
Lidocaine 4% patches (Aspercreme, IcyHot, and others)
are available over the counter for back, neck, shoulder,
and joint pain.
Annovera - A New Contraceptive Vaginal Ring
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
elevations.
DRUG INTERACTIONS — Drugs that induce hepatic
enzyme activity, such as rifampin, some protease ...
Annovera (TherapeuticsMD), a contraceptive vaginal
ring that releases segesterone acetate, a synthetic
progestin, and ethinyl estradiol, was approved by the
FDA in 2018 and is now available. It is the first product
to contain segesterone and the second vaginal ring
to become available in the US; NuvaRing, which
delivers etonogestrel and ethinyl estradiol, was the
first. Unlike NuvaRing, which requires use of a new
ring each month, the Annovera ring can be used for
an entire year, but it must be removed for one week
each month.
Finerenone (Kerendia) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
was hyperkalemia
(18% vs 9% with placebo). Hyponatremia and hypotension
also occurred.
DRUG INTERACTIONS ...
Finerenone (Kerendia – Bayer), an oral nonsteroidal
mineralocorticoid receptor antagonist (MRA), has
been approved by the FDA to reduce the risk of
sustained eGFR decline, end-stage renal disease,
nonfatal MI, hospitalization for heart failure (HF), and
cardiovascular death in adults with chronic kidney
disease (CKD) associated with type 2 diabetes. It is the
first nonsteroidal MRA to be approved in the US.
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
or breastfeeding women is not expected
to cause harm to the fetus or the breastfed infant.
DRUG INTERACTIONS ...
The FDA has approved the sodium/hydrogen
exchanger 3 (NHE3) inhibitor tenapanor (Xphozah –
Ardelyx) to reduce serum phosphorus in adults with
chronic kidney disease (CKD) on dialysis as add-on
therapy when phosphate binders are ineffective or
as monotherapy when phosphate binders cannot be
tolerated. Tenapanor is the first NHE3 inhibitor to be
approved in the US for hyperphosphatemia. It was
previously approved as Ibsrela to treat irritable bowel
syndrome with constipation (IBS-C).
Med Lett Drugs Ther. 2024 Mar 4;66(1697):38-9 doi:10.58347/tml.2024.1697b | Show Introduction Hide Introduction
Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 24, 2017 (Issue 1519)
( ...
The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human
monoclonal antibody, for treatment of adults with
moderate to severe atopic dermatitis (eczema) that
has not responded to topical therapies. It can be used
with or without topical corticosteroids.
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020 (Issue 1596)
. Diazepam and midazolam
are classified as schedule IV controlled substances.
DRUG INTERACTIONS — Diazepam ...
The FDA has approved nasal spray formulations of
the benzodiazepines diazepam (Valtoco — Neurelis)
and midazolam (Nayzilam — UCB) for acute treatment
of intermittent episodes of frequent seizure activity
(seizure clusters). Diazepam rectal gel (Diastat, Diastat
AcuDial, and generics) has been used for this indication
for many years.
Twirla - A New Contraceptive Patch
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
) February 8, 2021
DRUG INTERACTIONS — Drugs that induce hepatic
enzyme activity, such as rifampin, can ...
The FDA has approved Twirla (Agile Therapeutics),
a transdermal contraceptive patch containing the
estrogen ethinyl estradiol and the progestin
levonorgestrel, for use in women with a BMI <30 kg/m2.
It is the second contraceptive patch to become
available in the US; Xulane, a patch that delivers
ethinyl estradiol and the progestin norelgestromin,
has been available since 2014.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
,
and alopecia were also common.
DRUG INTERACTIONS — SN-38 is metabolized by
uridine diphosphate-glucuronosyl ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.